NCT00042939 2023-07-06
Irinotecan and Docetaxel With or Without Cetuximab in Treating Patients With Metastatic Pancreatic Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
Clinical Trials
13 trialsNCT00305760 2020-02-19
Vaccine Therapy, Cyclophosphamide, and Cetuximab in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00276744 2018-10-24
Individualized Drug Treatment for Treating Patients With Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT00408564 2018-07-23
Cetuximab, Gemcitabine, and Oxaliplatin Followed By Surgery or External-Beam Radiation Therapy and Capecitabine in Treating Patients With Locally Advanced, Nonmetastatic Pancreatic Cancer That Cannot Be Removed By Surgery
Medical University of South Carolina
Phase 2 Completed
NCT02241187 2017-09-27
Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection
Memorial Sloan Kettering Cancer Center
Phase NA Completed
NCT00424827 2017-06-01
A Trial of Chemo & Radiation Therapy for Pancreatic Cancer
University of Massachusetts, Worcester
Phase 2 Completed
NCT00871169 2016-06-14
Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer
New Mexico Cancer Research Alliance
Phase 2 Completed
NCT00383149 2016-03-10
A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer
R-Pharm
Phase 2 Completed
NCT00225784 2014-07-16
Cetuximab, Radiotherapy and Twice Weekly Gemcitabine to Treat Pancreatic Cancer
Dartmouth-Hitchcock Medical Center
Phase 2 Completed
NCT00305877 2014-05-21
Bevacizumab or Cetuximab And Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Pacreatic Cancer That Has Been Completely Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT00091026 2014-05-15
Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00338039 2013-03-22
Induction Cetuximab (IM-C225), Gemcitabine, and Oxaliplatin in Pancreatic Cancer Patients
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00326911 2011-05-25
Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic Cancer
Eli Lilly and Company
Phase 2 Terminated